Institut Pasteur De Lille

Institut National De La Sante Et De La Recherche Medicale

Other

Centre National De La Recherche Scientifique

Institut Pasteur

The University of Tennessee Research Foundation

Centre National De La Recherche Scientifique-cnrs

Helene Gras-Masse

Andre Tartar

Christian Sergheraert

Elisabeth Gomard

Remy Magne

Frederic Martinon

Christophe Boutillon

Jean-Paul Levy

Louis A Chedid

Francoise Marguerite Audibert

Edwin H Beachey

Oleg Melnyk

Line Bourel

Jean-Sebastien Fruchart

Michel Jolivet

Jean Gerard Guillet

Estelle Loing

Claudie Verwaerde

Kader Thiam

The invention relates to a functionalised solid support for the synthesis of compounds comprising at least one &#x3b1;-oxoaldehyde function, to a process for preparing it and to its applications, in particular for the preparation of a library of organic compounds, of a diagnostic reagent, of a microtitration plate and of a biochip, such as a DNA chip. The present invention also relates to a process for the synthesis of organic compounds comprising at least one &#x3b1;-oxoaldehyde function and to the &#x3b1;-oxoaldehyde peptides obtained using this process.

Functionalised solid support for alpha-oxoaldehyde synthesis

The invention concerns any lipopeptide characterized in that it comprises: a peptide part comprising the peptide sequence consisting of about 30 to about 50 of the last contiguous amino acids of the interferon-&ggr; (IFN-&ggr;) C-terminal end of mammals, whereof, if required, the last 3 to 20 amino acids have been suppressed; and one or several lipophilic parts comprising C4-C20 chain of carbon atoms, saturated or unsaturated, linear or branched, or a steroid group. The invention also concerns any lipopeptide such as defined above containing one or several CD8, and/or CD4, and/or B epitopes. The invention further concerns medicines or vaccines containing any polypeptide such as defined above.

Lipopeptides containing an interferon-&ggr; fragment, and uses thereof in pharmaceutical compositions

Cytotoxic lymphocyte-inducing lipopeptides comprising a peptide part having between 10 and 40 amino acids approximately and comprising at least one tigenic determinant. The lipopeptides also comprise one or more chains derived from fatty acids and one or more modified steroid groups. Said lipopeptides may be used for immunizing the human or animal body against pathogenic agents such as viruses or parasites. The peptide part may, in particular, be a fragment of the protein encoded by the ENV gene, by the NEF gene or by the GAG gene of HIV viruses.

Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines

Cytotoxic lymphocyte-inducing lipopeptides comprising a peptide fragment having approximately between 10 and 40 amino acids and comprising at least one antigenic determinant and also comprising one or more chains derived from fatty acids and one or more modified steroid groups useful for immunizing a human or animal body against pathogenic agents such as viruses or parasites which fragment is preferably a fragment of the protein encoded by the ENV gene, by the NEF gene or by the GAG gene of HIV viruses.

Cytotoxic T lymphocyte-inducing lipopeptides and methods of use

Cytotoxic lymphocyte-inducing lipopeptides comprising a peptide part having between 10 and 40 amino acids approximately and comprising at least one antigenic determinant. The lipopeptides also comprise one or more chains derived from fatty acids and one or more modified steroid groups. Said lipopeptides may be used for immunizing the human or animal body against pathogenic agents such as viruses or parasites. The peptide part may, in particular, be a fragment of the protein encoded by the ENV gene, by the NEF gene or by the GAG gene of HIV viruses. DA.

Peptide fragment of M protein of S. pyrogenes elecit opsonic antibodies which are type-specific for type 24 streptococci.

Synthetic peptide compounds

Growing community of inventors

Merignies, France

Helene Gras-Masse